S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?
-
Letto da:
-
Di:
A proposito di questo titolo
Drs Jeffrey Swigris and Ayodeji Adegunsoye discuss fibrosing interstitial lung disease and treatment challenges for individuals with idiopathic pulmonary fibrosis.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982422). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Idiopathic Pulmonary Fibrosis (An Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline https://pubmed.ncbi.nlm.nih.gov/35486072/
Health-Related Quality of Life and Symptoms in Patients With IPF Treated With Nintedanib: Analyses of Patient-Reported Outcomes From the INPULSIS® Trials https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990488/
Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Clinical Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089322/